Suivre ce blog
Administration
Connexion
+
Créer mon blog
Publicité
Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
Home
ML7 Project
Tests Results
Patents
News
Financing
Publications
Clinical Trials
Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
>
Categories
>
Patents
5 mars 2015
USE OF RHO KINASE INHIBITORS IN THE TREATMENT OH HEARING LOSS
USE OF RHO KINASE INHIBITORS IN THE TREATMENT OH HEARING LOSS, TINNITUS AND IMPROVING BODY BALANCE Link: B1650PC00_US20050222127
Publicité
Publicité
25 février 2015
PUBLICATION INTERNATIONALE BREVET ML7 SYNTHESIS
Lien: B1650PC00_Publication
6 février 2015
TREATMENT OF AN INFLAMMATION OF THE TARSAL GLAND OF THE EYELID
Lien: PROJET_TARSAL_NEUROPTIS TREATMENT OF AN INFLAMMATION OF THE TARSAL GLAND OF THE EYELID The present invention relates to a method for treating an inflammation and/or dilatation of the tarsal gland (or meibomian gland) of the eyelid. Inflammation...
20 décembre 2014
NEUROPTIS BIOTECH PATENTS
- Effect of ML7 on occular surface diseases: Europe, USA - Effect of ML7 on adult depression: Europe - Synthesis of ML7 molecule and formulation as a non preserved eyedrop: Europe, USA, Japan (pending) - Effect of Spasfon Inj. on severe Cluster Headache...
Publicité
Publicité
Recherche
Publicité
Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
ML7 - Neuroptis Biotech - MLCK Inhibitor - Dry Eye Syndrome - Glaucoma - Myosin Light Chain Inhibitor - Sécheresse oculaire - Glaucome - Inhibiteur des chaines légères de Myosine.
Accueil du blog
Créer un blog avec CanalBlog
Newsletter
Email
Contacter le propriétaire du blog
Catégories
Dry Eye
Ded
2015
Publications
Ml7
Treatment
Diagnosis
News
Meibomian
Tarsal Glands Meibomius Glands Protection
Tarsal Glands Meibomius Glands Dysfunction
Mlck Inhibitor
New Therapies
Mlck
Tearfilm Quality
2014
Case Control Study
Research
Sjögren's Syndrome
Formulation
Medical Device
Tearscience Website
Clinical Trial
Patents
Animals Efficacy
Biotech Finances
Drug Development
Visiteurs
Depuis la création
33 343
Flux RSS
Publicité